Phosphoryl Prodrugs: Characteristics to Improve Drug Development

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Development

Background:

• Biologically active phosphoryl compounds often exhibit poor pharmacokinetic (PK) profiles due to negative charges.
• Prodrug strategies are essential for improving the PK of active pharmaceutical ingredients.
• Lipophilic modifications mask phosphoryl group charges, enabling the release of active molecules.

Purpose of the Study:

• To review trends in pharmacokinetic parameters for phosphoryl prodrugs.
• To highlight advancements in terminal elimination half-life, Cmax, clearance, oral bioavailability, and cLogP.
• To focus on ester, amidate, and ProTide prodrug families.

Main Methods:

• Literature review of phosphoryl prodrug research.
• Analysis of pharmacokinetic data including half-life, Cmax, clearance, oral bioavailability, and cLogP.
• Categorization of prodrugs into esters, amidates, and ProTides.

Main Results:

• Phosphoryl prodrugs demonstrate improved pharmacokinetic properties.
• Lipophilicity plays a key role in the success of prodrug design.
• Specific trends in half-life, Cmax, clearance, oral bioavailability, and cLogP were identified.

Conclusions:

• Moderating lipophilicity is a critical factor for successful phosphoryl prodrug development.
• Prodrug evaluation is vital for advancing drug development across all clinical applications.
• This analysis contributes to the ongoing evolution of prodrug strategies.